Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026

Reuters
2026.03.11 18:07
March 11 (Reuters) - BridgeBio Pharma Inc (BBIO.O) : * BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9 * BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026 * BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer